Content Rheum | JAKi | RhAPP

top of page

Content Rheum

JAK

FAQs

Click a title to watch the FAQ

Describe JAK-STAT Signaling in Inflammation.

Provide Immunologic Rationale For JAK Directed Therapy In Rheumatic Disease.

Describe the Variability in JAK Enzyme Inhibition Specificity Among the Available JAK Inhibitors and Discuss the Potential Clinical Implications of These Differences.

What is the ORAL Surveillance Study and How Can it be Applied to Clinical Practice?

Is There a Widely Accepted Definition of Remission in Rheumatoid Arthritis and How Likely are Patients to Achieve Remission on Advanced Therapeutics?

Medication Review_v2.png

MEDICATION REVIEWS

Click a title to watch the medication review

Describe the Mechanism of Action of Upadacitinib.

How is Upadacitinib Dosed Across Rheumatologic Indications?

What is the Safety Profile of Upadacitinib Across Indications?

JOURNAL CLUBS

Long-Term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data From SELECT-COMPARE.

Safety and Efficacy of Upadacitinib For Pediatric Patients With Polyarticular Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-Label, Phase-1 Trial.

PODCASTS

Navigating Remission in Rheumatoid Arthritis: Approaches, Advances, Impact, and Insights

Lost Time: The Impact of Delaying Optimal Therapy in Patients With Rheumatoid Arthritis and Spondyloarthropathies Who Haven't Achieved Disease Control

From Prescription to Possession: Understanding Medicare Access & Cap and Smooth

Become a RhAPP Member

bottom of page